BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,814,474 | -16.6% | 26,656 | 0.0% | 0.03% | -13.3% |
| Q2 2023 | $2,175,929 | +6.0% | 26,656 | -3.6% | 0.03% | 0.0% |
| Q1 2023 | $2,051,799 | -10.2% | 27,656 | +0.4% | 0.03% | -16.7% |
| Q4 2022 | $2,283,841 | +15.5% | 27,556 | +295.7% | 0.04% | +9.1% |
| Q3 2022 | $1,977,000 | -18.1% | 6,964 | 0.0% | 0.03% | -15.4% |
| Q2 2022 | $2,414,000 | -19.9% | 6,964 | 0.0% | 0.04% | -2.5% |
| Q1 2022 | $3,015,000 | -17.5% | 6,964 | -1.4% | 0.04% | -11.1% |
| Q4 2021 | $3,655,000 | +7.6% | 7,064 | +0.8% | 0.04% | -2.2% |
| Q3 2021 | $3,397,000 | +1.8% | 7,009 | -5.4% | 0.05% | +7.0% |
| Q2 2021 | $3,336,000 | +18.4% | 7,409 | +0.4% | 0.04% | +10.3% |
| Q1 2021 | $2,817,000 | +17.1% | 7,377 | -2.6% | 0.04% | +14.7% |
| Q4 2020 | $2,406,000 | +34.7% | 7,577 | +5.1% | 0.03% | +13.3% |
| Q3 2020 | $1,786,000 | -6.2% | 7,210 | 0.0% | 0.03% | -14.3% |
| Q2 2020 | $1,904,000 | +39.3% | 7,210 | 0.0% | 0.04% | +16.7% |
| Q1 2020 | $1,367,000 | -13.6% | 7,210 | 0.0% | 0.03% | +7.1% |
| Q4 2019 | $1,582,000 | +13.7% | 7,210 | +1.4% | 0.03% | +7.7% |
| Q3 2019 | $1,391,000 | -6.2% | 7,110 | 0.0% | 0.03% | -7.1% |
| Q2 2019 | $1,483,000 | +6.2% | 7,110 | +1.1% | 0.03% | 0.0% |
| Q1 2019 | $1,397,000 | +38.9% | 7,032 | +1.2% | 0.03% | +21.7% |
| Q4 2018 | $1,006,000 | -29.1% | 6,947 | 0.0% | 0.02% | -14.8% |
| Q3 2018 | $1,418,000 | +40.0% | 6,947 | +1.5% | 0.03% | +28.6% |
| Q2 2018 | $1,013,000 | -2.1% | 6,847 | 0.0% | 0.02% | -4.5% |
| Q1 2018 | $1,035,000 | +16.7% | 6,847 | 0.0% | 0.02% | +15.8% |
| Q4 2017 | $887,000 | +8.8% | 6,847 | +1.5% | 0.02% | +5.6% |
| Q3 2017 | $815,000 | +2.8% | 6,747 | 0.0% | 0.02% | 0.0% |
| Q2 2017 | $793,000 | +15.8% | 6,747 | 0.0% | 0.02% | +12.5% |
| Q1 2017 | $685,000 | -1.3% | 6,747 | 0.0% | 0.02% | -5.9% |
| Q4 2016 | $694,000 | -6.1% | 6,747 | 0.0% | 0.02% | -10.5% |
| Q3 2016 | $739,000 | -2.9% | 6,747 | 0.0% | 0.02% | -5.0% |
| Q2 2016 | $761,000 | +19.3% | 6,747 | 0.0% | 0.02% | +17.6% |
| Q1 2016 | $638,000 | +6.7% | 6,747 | +1.5% | 0.02% | +6.2% |
| Q4 2015 | $598,000 | -2.6% | 6,647 | 0.0% | 0.02% | -11.1% |
| Q3 2015 | $614,000 | -6.3% | 6,647 | 0.0% | 0.02% | +5.9% |
| Q2 2015 | $655,000 | -0.2% | 6,647 | +1.5% | 0.02% | 0.0% |
| Q1 2015 | $656,000 | +11.8% | 6,547 | +3.2% | 0.02% | +6.2% |
| Q4 2014 | $587,000 | – | 6,347 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |